PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.\', \'Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.\', \'Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.\', \'School of Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.\', \'Molecular and Cellular Biochemistry, Indiana University, Bloomington, IN 47405, USA.\', \'Institute for Protein Innovation, Boston, MA 02115, USA.\', \'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.\', \'Ligand Pharmaceuticals Inc., San Diego, CA 92121, USA.\', \'Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: dwkulp@wistar.org.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S2211-1247(22)00029-810.1016/j.celrep.2022.110318
?:hasPublicationType
?:journal
  • Cell reports
is ?:pmid of
?:pmid
?:pmid
  • 35090597
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 7.552
?:rankingScore_hIndex
  • 92
is ?:relation_isRelatedTo_publication of
?:title
  • Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35090597>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35090597>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all